PPARS, insulin resistance and type 2 diabetes.

Area of Science:

• Pharmacology
• Endocrinology
• Metabolic Diseases

Background:

• Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors regulating glucose and lipid metabolism.
• PPARgamma receptor agonists, such as rosiglitazone and pioglitazone, are established treatments for type 2 diabetes.
• Current therapeutic applications face limitations in licensing and require further clinical outcome data.

Purpose of the Study:

• To evaluate the therapeutic potential of PPAR receptor agonists in managing type 2 diabetes.
• To assess the impact of these agents on insulin sensitivity, glucose homeostasis, and lipid profiles.
• To explore their broader effects on vascular disease markers and long-term disease progression.

Main Methods:

• Review of clinical trial data and existing literature on PPARgamma agonists.
• Analysis of surrogate endpoints (glucose, lipids) and clinical outcomes.
• Comparison of efficacy and safety profiles with existing diabetes medications like metformin.

Main Results:

• PPARgamma agonists demonstrate significant improvements in insulin sensitivity, glucose, and lipid homeostasis.
• Potential benefits extend to coagulation, blood pressure, and microalbuminuria, impacting vascular disease.
• Favorable tolerability and renal function profile compared to metformin, with limited evidence of hepatic toxicity.

Conclusions:

• PPAR agonists represent a promising therapeutic avenue for type 2 diabetes, offering multifaceted metabolic and vascular benefits.
• Further clinical outcome studies are crucial to confirm surrogate marker improvements and expand therapeutic indications.
• Tailoring PPAR agonist compounds may optimize efficacy and minimize side effects like fluid retention and weight gain.